GL
GSK plc
GLAXF · OTC
$24.56 +2.33% (+$0.56)
1M -3.69%
Market Cap £71.2B
P/E Ratio 16.41x
Div. Yield 3.79%
ROE 25.57%
Bulios Fair Price
$36.46
48.5% upside
Current Price
$24.56
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GLAXF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
83 /100
Cheap EV/EBITDA 8.74x
P/S 2.29x
P/B 4.07x
Growth
35 /100
Stable Rev. growth 3.66%
FCF growth 4.99%
Book val. growth 15.61%
Profitability
89 /100
Strong Net margin 13.93%
Op. margin 18.33%
FCF margin 20.46%
Quality
72 /100
Excellent ROE 25.57%
ROA 7.08%
Asset turnover 0.51x
Debt
64 /100
Moderate Current ratio 0.82x
Int. coverage 11.82x
Net debt/EBITDA 1.52x
Stability
51 /100
Moderate Rev. volatility 0.38%
EPS volatility 105.48%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GLAXF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Luke Victor Miels
Employees
66,841
Headquarters
London
Upcoming events
28 OCT
Earnings
Upcoming earnings report